Over the past decade, clinical and basic research has demonstrated that estrogen has a dramatic impact on the response to vascular injury and the development of atherosclerosis. Further work has indicated that this is at least partially mediated by an enhancement in nitric oxide (NO) production by the endothelial isoform of NO synthase (eNOS) due to increases in both eNOS expression and level of activation. The effects on eNOS abundance are primarily mediated at the level of gene transcription, and they are dependent on estrogen receptors (ERs), which classically serve as transcription factors, but they are independent of estrogen response element action. Estrogen also has potent nongenomic effects on eNOS activity mediated by a subpopulation of ER␣ localized to caveolae in endothelial cells, where they are coupled to eNOS in a functional signaling module. These observations, which emphasize dependence on cell surface-associated receptors, provide evidence for the existence of a steroid receptor fast-action complex, or SRFC, in caveolae. Estrogen binding to ER␣ on the SRFC in caveolae leads to G ␣i activation, which mediates downstream events. The downstream signaling includes activation of tyrosine kinase-MAPK and Akt/protein kinase B signaling, stimulation of heat shock protein 90 binding to eNOS, and perturbation of the local calcium environment, leading to eNOS phosphorylation and calmodulinmediated eNOS stimulation. These unique genomic and nongenomic processes are critical to the vasoprotective and atheroprotective characteristics of estrogen. In addition, they serve as excellent paradigms for further elucidation of novel mechanisms of steroid hormone action. (Endocrine Reviews 23: 2002) 
with marked effects on the vasculature that are mediated, at least in part, by increased availability of the signaling molecule nitric oxide (NO) (1, 2) . The endothelial isoform of NO synthase (eNOS) is the principal source of NO in the vascular wall (3) . This article will review our current knowledge of estrogen modulation of eNOS expression and activity in vascular endothelium. The role of estrogen and NO in vascular function and disease in humans will first be summarized. Important insights obtained in animal models will also be addressed. Recent investigations in cell culture revealing that the actions of estrogen on eNOS are both genomic and nongenomic in nature will be discussed. In addition, the roles of the two known estrogen receptor (ER) isoforms, ER␣ and ER␤, will be described. Finally, the cellular and molecular mechanisms underlying the genomic and nongenomic regulation of eNOS by estrogen will be considered in depth. Further knowledge about the complex impact of estrogen on endothelial cell biology is needed to understand the normal actions of the hormone in the cardiovascular system, and to guide future considerations of hormone therapy to prevent or treat cardiovascular disease (4).
II. Estrogen, Nitric Oxide, and Vascular Function and Disease in Humans

A. Estrogen and human vascular disease
The dramatic impact of estrogen on cardiovascular health is apparent from population-based studies, which indicate that premenopausal women have very little coronary artery disease compared with men, that the incidence of the disease rises markedly after menopause, and that hormone replacement therapy (HRT) under certain conditions reduces the risk to premenopausal levels (5) (6) (7) (8) . In addition, women who undergo surgical menopause without estrogen replacement have two times the risk of coronary artery disease than other premenopausal women (9) . Whereas the mechanisms underlying these findings are not completely understood, considerable emphasis has been placed previously on the capacity of the hormone to modify circulating lipid levels (10) . However, only approximately one third of the clinical advantages of estrogen can be attributed to effects on lipid balance (6, (11) (12) (13) . Instead, recent evidence indicates that estrogen acts directly on the blood vessel wall to provide a major atheroprotective effect (14) .
B. Sources of estrogens in humans
The estrogen compounds to which the vascular endothelium may be exposed in women are multiple, and they arise from both endogenous and exogenous sources. Before menopause, the major endogenously derived circulating estrogen compound is 17␤-estradiol (E 2 ) produced by the ovary. Other endogenous estrogens and estrogen metabolites have also been described. After menses, when circulating E 2 levels increase and begin to cycle, levels range from less than 0.36 nm during the follicular phase to 2.8 nm during midcycle. During pregnancy, estrogen levels rise to 70 nm due to placental production, which increases near term and further with the onset of parturition. After menopause, E 2 concentrations fall to levels that are equivalent to those in males (0.04 -0.21 nm). During menopause, the primary form of endogenous circulating estrogen is estrone derived peripherally from androstenedione by conversion in adipose tissue (15) . Endothelial cells in both women and men may also be exposed to estrogens derived from the local conversion of testosterone or ⌬ 4 -testosterone to E 2 by aromatase (16) . Aromatase, E 2 -hydroxysteroid dehydrogenase, and 17-ketoreductase enzyme activities were first demonstrated in rat arterial vascular smooth muscle (VSM) cells in cell culture (17) , and more recently aromatase expression was noted in human VSM by in situ hybridization (18) . Only trace levels were detected in samples from infants, and greater aromatase mRNA and activity were found in adult samples. In addition, studies in cultured human VSM demonstrated upregulation of aromatase mRNA in response to cAMP, phorbol ester, or dexamethasone (18) . Thus, there is evidence that aromatase expression in VSM is developmentally regulated and also modulated by multiple signal transduction pathways and by glucocorticoids. However, the relative impacts of circulating vs. locally derived estrogens on endothelial cell function have not yet been clearly elucidated.
In addition to endogenously derived estrogens, there are often important exogenous sources in humans. Contraception is frequently accomplished using a combination of ethinyl E 2 and levonorgostrel or norethindrone. HRT is also often provided to postmenopausal women. This is frequently in the form of conjugated equine estrogens, and other oral and transdermal forms are also often considered. HRT frequently entails conjugated equine estrogens in combination with medroxyprogesterone acetate. In addition, selective estrogen receptor modulators, or SERMs, such as raloxifene are used for the treatment of osteoporosis, and it is likely that vascular-specific SERMS will also soon be available. Furthermore, phytoestrogens are a class of compounds found in certain plant-derived beverages and foods, and they have both estrogenic and antiestrogenic effects (14, 19, 20) . As such, the endothelium may be exposed to a variety of forms and levels of estrogen compounds depending on the sex and age of the individual, his/her diet, and therapies that he/she may be receiving.
C. Long-term effects of estrogen on eNOS function
The onset of menopause provides a natural model of estrogen deprivation in which the effects of endogenous levels of the hormone on vascular function can be revealed. In studies of changes in brachial artery diameter after reactive hyperemia, which provides an assessment of flow-mediated, endothelium-dependent, and NO-dependent vasodilation, responses were greater in premenpausal vs. postmenopausal women (21) . Similarly, determinations of forearm blood flow constrictor responses to NOS antagonism with l-N G -monomethyl arginine (l-NMMA), which also evaluate vascular NO activity, revealed greater constriction in premenopausal vs. postmenopausal women. Importantly, blood flow responses to the NO donor glyceryl trinitrate (GTN) were similar in the two study groups, indicating comparable VSM responses to NO. As might be predicted, the responses in postmenopausal women were comparable to those observed in men ( Fig. 1 and Ref. 22) .
The menstrual cycle certainly provides another natural model of varying estrogen status. In studies of healthy young women, the capacity for endothelium-dependent vasodilation in the brachial artery paralleled serum E 2 levels, and, additionally, there was evidence of progesterone antagonism of this effect (23, 24) . More recently, endothelium-dependent responses to bradykinin in resistance vessels have also been observed to be enhanced at midcycle during the period of greatest serum E 2 levels, whereas responses to GTN are unchanged ( Fig. 2 and Ref. 25) . In agreement with these findings, sex hormone deprivation after ovariectomy for uterine leiomyoma is associated with a decline in endotheliumdependent vasodilation, whereas the response to the NO donor sodium nitroprusside is unaltered (26) . Although the exact sources of NO are undetermined, the enhanced endothelium-dependent vasodilation observed during periods of greater estrogen abundance during the menstrual cycle correlates with higher serum levels of the NO metabolites nitrate and nitrite and greater exhaled NO (23, 27, 28) . Thus, although many other parameters may vary in parallel with the changes in estrogen status that accompany menopause or surgical ovariectomy or the menstrual cycle, there is a strong correlation between endogenous estrogen levels and the capacity for endothelial NO production in women.
The effects of HRT also provide insights into NOS regulation by estrogen. In landmark studies reported in 1994 it was demonstrated that endothelium-dependent vasodilation of the brachial and coronary arteries is enhanced after estrogen replacement therapy in postmenopausal women (29, 30) . Estrogen replacement therapy also causes elevations in plasma NO and NO metabolites (31, 32) . In addition, there is evidence that forearm blood flow constrictor responses to NOS antagonism are greater after estrogen replacement therapy, whereas responses to glyceryl trinitrate are unchanged, indicating augmented basal NO availability (22) . Furthermore, flow-mediated, endothelium-dependent vasodilation of the brachial artery is enhanced similarly by HRT with estrogen and by raloxifene therapy, whereas endotheliumindependent responses are not altered (Fig. 3) . In addition, the interventions yield comparable increases in plasma NO levels (33) . Interestingly, the inclusion of progestin in postmenopausal HRT appears to blunt the effects of estrogen on endothelial NO production (21) , perhaps paralleling the findings noted above for variations in endothelial function during the menstrual cycle (24) . Premenopausal women receiving estrogen replacement after ovariectomy also have enhanced endothelial function after therapy, and similar effects have been documented in young women receiving oral contraceptives (34) . Long-term estrogen administration also improves vascular function in males, and this is at least partially mediated through endothelium-derived NO (35, 36) . As such, prolonged exposure to exogenously derived estrogen has positive effects on endothelium-derived NO availability, which parallel those noted with altered endogenous levels and provides further evidence of potential longterm modulation of eNOS function by the hormone in humans. 
D. Short-term effects of estrogen on eNOS function
There is also evidence of short-term effects of estrogen on eNOS function in humans. In key early studies reported in 1994, iv ethinyl E 2 was found to cause a direct decrease in coronary vasomotor tone within 15 min in postmenopausal women (Fig. 4) . In addition, ethinyl E 2 caused attenuation of vasoconstrictor responses to acetylcholine (Ach) when given 15 min before Ach (37) . Experiments with intracoronary E 2 administered in a manner yielding premenopausal levels did not demonstrate changes in basal coronary vasomotor tone, but there was greater vasodilatory response to Ach when E 2 and Ach were given simultaneously. In these studies, E 2 had no effect on vasodilation with sodium nitroprusside, suggesting that the hormone rapidly modifies the availability of endothelium-derived NO (38) . Findings were similar when E 2 effects on forearm vascular responses were assessed in postmenopausal women, with the exception that endothelium-independent vasodilation was also enhanced (39) . In further studies in the coronary circulation of older women, the capacity of E 2 to cause augmented Ach-induced responses was prevented by NOS antagonism, providing additional evidence that the underlying mechanism involves enhanced bioavailability of NO (40) . In contrast to the observations made in postmenopausal women, intracoronary E 2 administration to similarly aged men caused neither a change in basal vasomotor tone nor greater vasodilation with Ach tested 20 min later (41). However, the provision of iv conjugated estrogens 15 min earlier caused greater Achinduced coronary blood flow and less cold-induced coronary vasoconstriction in men (42, 43). In a similar manner, phytoestrogens cause direct, rapid, NO-dependent dilation of the forearm vasculature of both men and women, which is comparable in degree to that observed with E 2 (Fig. 5) . Lower concentrations of phytoestrogen also potentiate the vasodilatory response to Ach. It is important to note that the threshold concentration of phytoestrogen yielding these effects does not greatly exceed those found in East Asian subjects in whom dietary phytoestrogen intake has been suggested to contribute to an extremely low incidence of atherosclerosis and coronary artery disease (44). These cumulative observations indicate that, in addition to the long-term effects of estrogen and estrogen-like compounds on eNOS action, there are short-term effects on the bioavailability of NO. Importantly, these effects may generally be comparable in men and women, and the estrogen formulation is a critical variable.
E. Role of estrogen receptors
Little experimental data are available in humans to reveal the role of ER in vascular function and health in the intact state. However, a young adult male with a disruptive mutation in the ER␣ gene was found to have premature coronary artery disease at age 31 yr (45, 46). Flow-mediated vasodilation of the patient's brachial artery was also attenuated, whereas vasodilation with sublingual nitroglycerin was intact, suggesting a diminished capacity for endothelial NO production. Interestingly, rapid vasodilation in response to sublingual E 2 was normal (46). These observations may be explained by recent studies demonstrating that either ER␣ or More direct studies of ER involvement in endothelial NO production have been performed in isolated human mammary artery segments. In precontracted rings obtained from men at the time of coronary artery bypass surgery, E 2 at concentrations of 100 nm or greater caused relaxation that was prevented by either endothelium removal or NOS antagonism. The response to E 2 was also attenuated 71% by the ER antagonist tamoxifen. Although issues relating to the concentration of E 2 required for this in vitro response may be raised, these findings suggest that the short-term effects of E 2 on endothelial NO bioavailability in humans are mediated by endothelial ER (47).
III. Estrogen, NO, and Vascular Function and Disease in Animal Models
A. Estrogen, NO, and animal models of vascular disease
The impact of estrogen on the response to vascular injury has been vigorously investigated in rodent models. In studies of carotid artery injury in rats, E 2 attenuated the resulting intimal and medial hypertrophy in females but not in males, and the addition of medroxyprogesterone acetate blocked the protective effects of estrogen (48 -50). Estrogen also enhances endothelial recovery after vascular injury, as indicated by greater reendothelialization and greater endothelium-dependent relaxation in previously injured arterial segments. In these studies the augmented recovery was associated with increased capacity for NO production, but it was not determined whether the effect of estrogen is mediated by an up-regulation of eNOS abundance or activity (51, 52). It has also been noted that estrogen reduces neointimal formation in mice deficient in the inducible isoform of NOS to an extent that is similar to that seen in wild-type mice. Since the inducible form of NOS and eNOS are the principal forms of the enzyme found in the vasculature, these observations suggest that eNOS is the primary isoform involved in estrogen-mediated protection (53). An additional explanation is that estrogen may primarily modify vascular injury by promoting angiogenesis (54).
Animal models have also been employed to demonstrate that estrogen has an important impact on the function of atherosclerotic arteries. In pioneering studies by Williams and colleagues (55, 56), both long-term (26 months) and brief (20 min) E 2 treatment caused enhanced Ach-mediated vasodilation in atherosclerotic coronary arteries of female cynomologus monkeys. Similarly, long-term E 2 administration in hypercholesterolemic swine led to the preservation of endothelium-dependent relaxation (57). Perhaps more importantly, there is considerable animal evidence that estrogen modifies the development of atherosclerosis. This includes studies in cholesterol-fed rabbits in which both ethinyl E 2 and conjugated equine estrogen reduced atherosclerosis by 35% in the aortic arch and by 75-80% in the thoracic and abdominal aorta (58). Similarly, E 2 administration to apolipoprotein E (apoE)-deficient mice decreased the atherosclerotic lesion area in both males and ovariectomized females. Importantly, neither the less biologically active 17␣-estradiol nor tamoxifen affected lesion development in ovariectomized females in the apoE deficiency paradigm, and the beneficial effects of 17␤-estradiol were only partially explained by changes in plasma lipoprotein levels (59). The latter variable has been elegantly controlled in studies of cholesterol-clamped rabbits in which the antiatherogenic properties of estrogen remain apparent. In addition, in the cholesterol-clamped rabbits the capacity of estrogen to prevent cholesterol accumulation in the vascular wall was abolished by balloon catheter injury, suggesting that an intact endothelium is required (Fig. 6 ) (60, 61). Furthermore, in the same model NOS inhibition reduced the atheroprotection afforded by estrogen, and comparable observations were made with the SERM levormeloxifene ( Fig. 6 ). Moreover, the antiatherogenic effect of the hormone was preceded by an increase in NO production that was followed by diminished mononuclear-endothelial cell binding. It was noted additionally that the effect of E 2 was to increase the basal release of NO, whereas NO release by Ach and NOS abundance was unaltered (62, 63) . These cumulative observations suggest that the antiatherosclerotic characteristics of estrogen involve direct effects on the vascular endothelium, and that these effects may be primarily mediated by enhanced NO production unrelated to genomic effects of the hormone on eNOS expression.
B. Role of ER in animal models of vascular disease
The role of ER in the effects of estrogen on the response to vascular injury has been addressed using nonselective ER antagonism or genetically engineered mice. In models of carotid artery injury in wild-type mice, physiological levels of E 2 inhibited the increases in vascular medial area and smooth muscle cell proliferation that occur with injury (48, 64). Comparable findings were also obtained in ER␣-deficient and ER␤-deficient mice (64, 65) . Such observations suggested that either receptor isoform may be sufficient to mediate the effects of estrogen or that the effects are through a non-receptor-mediated process or through another unidentified ER. The first of these possibilities was addressed in recent studies of ER␣,␤ double knockout mice. In the double knockouts, E 2 did not prevent the injury-induced increase in vascular medial area. However, VSM cell proliferation continued to be attenuated by the hormone (66) . In contrast, in experiments in rats employing nonselective pharmacological ER antagonism, it has been observed that the vasoprotective effects of E 2 are completely inhibited (67) . The role of ER␣ in the antiatherogenic features of estrogen has also been addressed in a recent report. In mice deficient in apoE alone, E 2 reduced the size of atherosclerotic lesions and also their histological complexity, as previously observed (59). Plasma cholesterol levels were decreased by E 2 , but the degree of the effects of the hormone on atherogenesis could not be explained solely on the basis of changes in the plasma lipid profile. In contrast, in mice with disrupted apoE and disrupted ER␣, E 2 had a more modest effect on lesion size and total plasma cholesterol was unaltered. However, the complexity of the plaques was diminished by E 2 despite the absence of ER␣ (68) . As such, certain mechanisms whereby estrogen alters the vascular response to injury and the progression of atherosclerosis are evidently mediated by ER␣ or ER␤. However, the bases for multiple other processes are yet to be determined. Furthermore, in contrast to the evidence that strongly implicates an important role for eNOS in the hormonal modulation of atherogenesis, studies are yet to be performed to clarify the specific contribution of eNOS to E 2 -induced changes in vascular injury responses.
C. Long-term effects of estrogen on eNOS in animal models
There is considerable evidence from investigations in intact animal models that long-term estrogen exposure enhances the capacity for endothelial NO production. For example, E 2 treatment of rabbits for 4 d caused an increase in endothelium-dependent relaxation in femoral artery rings (69) . Using NOS antagonism, it has also been shown that bioassayable endothelium-derived NO is higher in thoracic aortas isolated from female vs. male rats (70) . The same group of investigators employed ER␣ knockout mice to demonstrate that there is a significant association between the abundance of ER and the basal release of NO (71) . In 1994 it was reported that steady-state eNOS mRNA levels are increased in guinea pig skeletal muscle during pregnancy and after E 2 FIG. 6. Estrogen attenuates aortic cholesterol accumulation in cholesterol-clamped rabbits. Studies were performed with or without NOS antagonism with nitro-L-arginine methyl ester (L-NAME). Estrogen had an antiatherogenic effect in the undamaged aorta (P Ͻ 0.05 vs. placebo, no L-NAME by ANOVA). In contrast, this effect was abolished by balloon catheter injury (bottom panel). Similar findings, although not as pronounced, were obtained for levormeloxifene (P Ͻ 0.05 vs. placebo, no L-NAME by ANOVA). The atheroprotective effects of estrogen and levormeloxifene were attenuated by simultaneous NOS antagonism (P Ͻ 0.05 for yes L-NAME vs. no L-NAME). Values are mean Ϯ SEM, n ϭ 13-18 per group. Solid bars, Without L-NAME; hatched bars, with L-NAME. [Reprinted with permission from: P. treatment. This may have been related to the induction of eNOS in endothelium, but it is notable that the cell specificity of eNOS up-regulation was not determined, and eNOS is expressed in skeletal myocytes (72, 73) . The long-term effects of estrogen on eNOS expression have been demonstrated in studies of the uterine circulation in sheep. It was reported in 1996 that after 3 d of systemic E 2 treatment, there was enhanced NO-dependent, endothelium-dependent relaxation, which was related to greater NOS enzymatic activity (74) . It has since been shown that eNOS abundance is up-regulated in uterine artery endothelium after both prolonged (days) and brief (2 h) E 2 treatment (75, 76) . Although E 2 -related effects on eNOS do not occur in certain systemic arteries in the sheep (75) , studies in rats have demonstrated dramatic eNOS up-regulation in cerebral microvessels after chronic E 2 treatment. Interestingly, the eNOS responses to E 2 in the cerebral microvessels were similar in female and male rats (77) . In addition, studies with knockout mice have demonstrated that the E 2 -induced up-regulation in eNOS expression in the cerebral microvessels is mediated by ER␣, and that parallel changes occur in the abundance of cyclooxygenase type 1, which is the rate-limiting enzyme in prostacyclin production ( Fig. 7) (78) . Furthermore, work in porcine coronary arteries has shown that the effects of E 2 are direct and not mediated by changes in blood flow, since isolated ring segments displayed greater NO-dependent relaxation after 18 -22 h exposure to E 2 in vitro (79) .
The capacities to up-regulate eNOS and to reverse endothelial dysfunction are not limited to endogenous forms of estrogen. In studies in sheep, the SERM raloxifene caused more than a 10-fold increase in uterine blood flow over 6 h and a 22% rise in coronary blood flow over 24 h, and these effects were at least partially NO dependent (80) . Raloxifene also prevented the decrease in NOS expression which occurs with ovariectomy in rats (81) . Furthermore, in rats it has been shown that the long-term administration of the phytoestogen ␣-zearalenol causes enhanced endothelial NO production, and the effect is fully prevented by the ER antagonist ICI 182,780, indicating that it is mediated by ER binding (82) . Chronic exposure to phytoestrogen also improves endothelial dysfunction induced by ovariectomy in rats (83) .
D. Short-term effects of estrogen on eNOS in animal models
Experiments in isolated segments of rabbit coronary artery, rat superior mesenteric artery, and rat aorta from female animals have demonstrated that physiological levels of E 2 cause rapid, NO-dependent, endothelium-dependent relaxation or rapid, NO-dependent inhibition of platelet aggregation (84 -86) . However, a considerable number of additional works have alternatively demonstrated NOindependent, endothelium-independent E 2 -mediated relaxation (87) (88) (89) . The varying results related to endothelial NO production may be due to differences in the species or vascular beds under study, as well as varying usage of precontraction. In addition, the estrogen status of the animal is critically important. Collins and colleagues (84) demonstrated that coronary artery rings from oophorectomized, estrogen-treated, and acutely estrogen-withdrawn rabbits display robust endothelium-dependent, NO-dependent relaxation to E 2 , whereas rings from oophorectomized, untreated or oophorectomized, estrogen-maintained rabbits display more modest responses (Fig. 8) . Interestingly, the SERM raloxifene caused rapid NO-dependent, endotheliumdependent relaxation of coronary artery rings from both male and female rabbits studied under conditions that yielded only NO-independent responses to E 2 (88) . In addition, 30-min in vitro exposure to phytoestrogen restored NOmediated relaxation in pulmonary arteries isolated from chronically hypoxic rats (90) . Thus, paralleling the findings related to endothelial NO-mediated responses in humans, studies in animals indicate that estrogen causes both longterm up-regulation of eNOS expression and rapid enhancement of eNOS enzyme activation. 
IV. Genomic Mechanisms of eNOS Regulation by Estrogen
A. Genomic regulation of eNOS expression by estrogen
The mechanisms by which long-term E 2 exposure increases eNOS abundance have been delineated in experiments in cultured endothelial cells. Studies reported in 1995 demonstrated that the capacity for NO production by human aortic endothelium is greater after 8 h or more of E 2 treatment at concentrations of approximately 10 nm or greater. eNOS protein levels were also increased (91) . Additional work in human umbilical vein endothelial cells (HUVEC) demonstrated that both tamoxifen and ICI 182,780 prevent the increase in eNOS. Immunocytochemical analysis revealed ER␣ expression in early-passage HUVEC and diminished levels of expression with additional passage (92) . Further studies in ovine endothelial cells demonstrated that E 2 induces increases in NOS enzymatic activity and eNOS protein abundance at concentrations of 0.1 nm E 2 or greater, and that these changes are accompanied by increases in eNOS mRNA levels. Transient transfection assays with a specific estrogenresponsive reporter system also demonstrated that endothelial ERs are capable of estrogen-induced transcriptional transactivation (93) . Similar observations have also been made in human osteoblast-like cells, consistent with other data suggesting that NO may mediate estrogen action in bone (94) . eNOS expression in neonatal and adult cardiac myocytes is also up-regulated by E 2 in an ER-dependent manner, potentially explaining some of the cardioprotective effects of the hormone (95) . In addition, estrogen treatment caused an increase in eNOS mRNA abundance in LNCaP human prostate carcinoma cells within 2-4 h of exposure. Interestingly, estrone sulfate, the most abundant circulating estrogen that may serve as a prehormone for the terminal biologically active estrogen E 2 in men, also up-regulated eNOS mRNA in LNCap cells, and the response required 48 h, suggesting conversion to E 2 (96).
B. Basis for eNOS up-regulation by estrogen
Work in human endothelial EA.hy 926 cells indicates that E 2 or the more stable 17␣-ethinyl E 2 enhances eNOS protein and mRNA abundance in the absence of changes in the stability of eNOS mRNA. Nuclear run-on assays showed that the increase in eNOS mRNA abundance is related to greater eNOS gene transcription. The impact of 17␣-ethinyl E 2 on eNOS gene transcription was further evaluated in transient transfection studies using a 1.6-kb human eNOS promoter fragment, which lacks classical estrogen response elements (EREs). Promoter activity was enhanced to a degree comparable to the increase in eNOS mRNA levels, and EMSAs suggested greater DNA-protein complex formation involving a putative Sp1 binding element after estrogen treatment. However, immunodepletion or supershift analyses were not performed to specifically identify the nuclear protein that is involved (97) . The role of ER subtypes in eNOS gene activation by E 2 has been elucidated in neonatal rat cardiac myocytes. eNOS up-regulation by E 2 was fully prevented by the ER␤-specific antagonist RR-tetrahydrochrysene (THC), indicating a primary role for that subtype (Fig. 9) (98) . Further work in cultured endothelial cells indicated that eNOS down-regulation by TNF␣, which is due to enhanced eNOS mRNA degradation, is prevented by E 2 , and that this mechanism is also ER dependent (99) . Thus, there is transcriptional regulation of eNOS expression by E 2 through mechanisms that do not involve classical ERE-mediated processes, and additional nontranscriptional mechanisms may be important under certain conditions. 
C. Other genomic mechanisms modifying eNOS function
The eNOS enzyme is localized to endothelial cell caveolae, which are lipid-ordered domains on the plasma membrane that compartmentalize signal transduction molecules. Within caveolae, there are multiple mechanisms that modify eNOS activity, including protein-protein interaction between the enzyme and the structural and regulatory protein caveolin, which leads to attenuated eNOS activity (100) . Studies in rat cerebral arterioles have demonstrated that chronic estrogen depletion (ovariectomy) causes a complete loss of Achinduced, endothelium-dependent relaxation, and this defect is associated with not only a decrease in eNOS expression, but also an up-regulation in caveolin abundance. In addition, these changes were mimicked by simultaneous interventions that decreased eNOS and increased caveolin abundance in animals with intact ovaries, and estrogen replacement normalized the Ach responses in the ovariectomized females at the same time that it up-regulated eNOS and down-regulated caveolin (101, 102) . In recent work in bovine aortic endothelial cells, eNOS expression was increased after 24 h of E 2 exposure, as seen in the intact animal; however, caveolin expression rose after 48 h of treatment. In addition, the increase in caveolin expression was prevented by ER antagonism. After E 2 , NO production was elevated at 24 h but not at 48 h, which would be consistent with greater caveolinrelated attenuation in eNOS activity at the later time point (103) . These cumulative findings suggest that the effects of E 2 on caveolin expression may have an important impact on eNOS function, but they also emphasize that factors such as the identity of the endothelial cell target, the cellular and tissue context of the experiment, and the timing of hormone exposure must be considered. In addition to the relative level of eNOS enzymatic activity, the ultimate bioavailability of NO as a signaling molecule is modified by the degree of scavenging by reactive oxygen species such as superoxide. In human endothelial cells, superoxide levels are dictated by the production of the radical by reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and its degradation by superoxide dismutase (SOD). In recent studies in HUVEC, E 2 caused a 60% decrease in the expression of the protein and mRNA for the NADPH oxidase subunit gp91phox. There was also a less dramatic, but significant, E 2 -induced decline in mRNA abundance for p22phox, which, together with gp91phox, constitute the membrane-bound cytochrome b558 portion of the NADPH oxidase complex. The two cytosolic activating fac- 
tors of the complex, p47phox and p67phox, were also downregulated by E 2 , and the net effect was an approximately 50% diminution in the capacity to produce superoxide. In addition, the effects of E 2 on NADPH oxidase subunit expression and superoxide production were prevented by ER antagonism. Heat shock protein 90 (HSP90) and eNOS expression were also up-regulated by E 2 . In contrast, levels of expression of the reactive oxygen species-metabolizing enzymes glutathione-peroxidase, copper/zinc SOD, manganese SOD, and catalase were not affected by E 2 ( Fig. 10 and Ref. 104) . Thus, in addition to up-regulating eNOS abundance, E 2 inhibits the expression of NADPH oxidase in endothelial cells, thereby potentially increasing the bioavailability of NO through more than one process.
V. Nongenomic Regulation of eNOS by Estrogen
A. Estrogen and eNOS activation
The bases for rapid effects of E 2 on eNOS function have been elucidated in studies of cultured endothelial cells. It was shown initially that estrogen acutely (5-10 min) stimulates eNOS activity, that the response is attenuated by ER antagonism but not by inhibition of gene transcription, and that ER␣ is expressed in cultured endothelial cells (Fig. 11 and Refs. 105-107). It has also been shown that the overexpression of ER␣ in endothelial cells causes enhancement of the acute response to E 2 that is blocked by ER antagonism and specific to E 2 vs. other agonists (Fig. 12) . In addition, the enhanced response is dependent on the ER␣ hormone binding domain. In COS-7 cells, which do not constitutively express ER or eNOS, the acute stimulation of eNOS by E 2 can be demonstrated after the cotransfection of ER␣ and eNOS cDNAs (107) . Raloxifene also activates endothelial cell eNOS within 10 min, and the process is ER dependent since it is abolished by ICI 182,780 (108) . eNOS activation by E 2 has also been observed in human bronchiolar epithelial cells, which also constitutively express the enzyme and ER␣, suggesting that mechanisms similar to those delineated in the vasculature may play a role in hormonal modulation of airway function (109) .
The signal transduction mechanisms by which E 2 activates eNOS have also been delineated. In experiments performed in ovine endothelial cells, tyrosine kinase inhibition completely prevented the response to E 2 . In addition, the specific MEK inhibitor PD98059 also fully negated eNOS stimulation by E 2 . Furthermore, E 2 caused a rapid increase in MAPK activity, and this effect was prevented by both tamoxifen and ICI 182,780 (Fig. 13) . These data indicate that the acute stimulation of eNOS by E 2 and ER␣ entails the activation of tyrosine kinase/MAPK (107) . There is also evidence of a role for the recruitment of the PI3-kinase-protein kinase B/Akt pathway. In studies of human endothelial cells, E 2 -induced eNOS activation was prevented by the PI3-kinase inhibitor, LY294002, and E 2 caused rapid Akt phosphorylation on serine 473. E 2 also caused eNOS phosphorylation on serine 1177, which is a critical residue for eNOS activation and modification of the sensitivity to cellular calcium levels (Fig.  14) . In addition, expression of a kinase-deficient, dominantnegative Akt prevented E 2 -stimulated NO production (110 -112) . Additional work suggests that E 2 -induced PI3-kinase/ Akt signaling is mediated exclusively by ER␣ and not ER␤, and that it entails direct interaction between ER␣ and the p85 subunit of PI3-kinase (111, 112) . Recent examinations of the signal transduction events by which raloxifene stimulates eNOS have also implicated involvement of MAPK and PI3-kinase/Akt signaling that is mediated by ER␣ (113) .
The role of calcium in E 2 -induced activation of eNOS has also been ascertained. In the two initial reports of eNOS stimulation in cultured endothelial cells, it was unclear whether calcium is involved. It was noted in studies in ovine endothelial cells that the removal of extracellular calcium completely prevented the response (105), yet changes in cytosolic calcium levels were not detected in parallel with eNOS activation by E 2 in HUVEC (106) . Later work in bovine aortic endothelial cells and human arterial endothelial cells indicated that there is a transient rise in intracellular calcium concentration upon E 2 exposure (114, 115) . Both E 2 -induced Akt activation and eNOS translocation from the plasma membrane upon E 2 stimulation have been found to be calcium dependent (112, 114) . These cumulative findings suggest that E 2 activation of eNOS is a calcium-dependent process, but global increases in intracellular calcium levels may not be required.
Additional mechanisms of eNOS regulation in addition to those involving protein kinase-mediated phosphorylation events and changes in calcium homeostasis have also been investigated. In studies of HUVEC, inhibitors of HSP90 function prevented E 2 -stimulated NO release and cGMP production. E 2 also was found to induce HSP90-eNOS association, and this event was prevented by ER antagonism, providing further evidence for a role for HSP90 in eNOS activation by E 2 (116) . Thus, the short-term effects of estrogen on eNOS that are central to cardiovascular physiology are mediated by ER functioning in a novel, nongenomic manner, and multiple signal transduction events are likely to be involved.
B. Localization of eNOS activation by estrogen to plasma membrane
Studies employing immunoidentification or conjugated estrogen have indicated that a subpopulation of ER may be associated with the cell surface in certain cell types (117, 118) . In fact, immunofluorescence experiments suggest that the ligand binding domain of the ER␣ may actually reside on the extracellular face of the plasma membrane (119) . As mentioned above, there is strong evidence that eNOS is targeted to the endothelial plasma membrane, particularly to caveolae, which are specialized, cholesterol-rich lipid-ordered domains that compartmentalize signal transduction. eNOS trafficking to caveolae is dependent upon the myristoylation and palmitoylation of the protein (100, 120 -122) . Initial determinations of the subcellular site of interaction between ER␣ and eNOS involved studies of plasma membranes isolated from ovine endothelial cells, in which eNOS stimulation was evaluated by measuring 3 H-l-arginine conversion to 3 H-l-citrulline (123) . In the absence of added calcium, calmodulin, or cofactors, 10 Ϫ8 m E 2 (15 min) caused a 92% increase in NOS activity compared with basal levels, whereas 17␣-estradiol (110) .] had no effect. Maximal NOS activity was assessed by replacing E 2 with a mixture of calcium, calmodulin, and cofactors, yielding a 170% rise in activity compared with no additives; E 2 (10 Ϫ8 m) did not enhance this activity (Fig. 15A ). These observations indicated that all of the signal transduction machinery necessary for eNOS stimulation by E 2 is associated with the plasma membrane. Since E 2 alone activated the enzyme to approximately half of maximal levels, the response is quite robust. Time course experiments with E 2 alone further revealed a progressive, linear increase in NOS activity during the first 30 min of incubation, followed by a plateau (Fig. 15B ). This contrasted with NOS activity with added calcium, calmodulin, and cofactors, which displayed linearity with time for at least 120 min (123) . These data suggest that the availability of one or more of these molecules is limited in the isolated membranes; in contrast, in intact cells there are most likely mechanisms that replenish these factors in the locale of the plasma membrane.
The role of ER in E 2 activation of plasma membrane eNOS was examined using the ER antagonist ICI 182,780, and the agent was found to completely prevent E 2 -stimulated NOS activity (Fig. 15C ). In addition, antibody to the ligand binding domain of ER␣ (TE111) blocked E 2 -stimulated NOS activation, whereas unrelated IgG had no effect (Fig. 15D ). These observations indicated that the response to E 2 is mediated by an ER or ER-like protein associated with the endothelial cell plasma membrane. Immunoidentification experiments, which compared the plasma membrane ER with cytosolic and nuclear ER using antibodies directed against three different ER␣ epitopes, were then performed. Antibodies directed against amino acids 495-595 (AER320), 302-553 (TE111), or 120 -170 of human ER␣ (AER304) all detected a single 67-kDa protein species in endothelial cell plasma membranes that was identical in size to the protein detected in nuclear and cytosolic fractions (Fig. 16A) . Confirmatory studies were done involving the localization of epitopetagged ER␣ (ER␣-myc) transiently transfected into COS-7 cells. Whereas antibody to ER␣ revealed no signal in sham- 
transfected cells, there was positive signal for ER␣ of comparable size in nucleus, cytosol, and plasma membrane from cells transfected with ER␣-myc. In parallel, immunoblot analysis with antibody to the myc tag revealed no signal in sham-transfected cells, but a protein of similar size was detected in the nucleus, cytosol, and plasma membranes of cells expressing the tagged receptor (Fig. 16B) . These cumulative findings indicate that E 2 -stimulated eNOS activity is mediated by a subpopulation of ER␣ that is associated with the endothelial plasma membrane (123) . Independent investigations demonstrating eNOS activation by membrane-impermeant E 2 conjugated to BSA have provided additional evidence of eNOS signaling by cell surface ER (110, 115) . The importance of plasma membrane colocalization for ER␣-stimulated eNOS activity was evaluated in a reconstitution paradigm in COS-7 cells. Plasma membranes from cells expressing eNOS and ER␣ displayed rapid ER-mediated NOS stimulation, whereas membranes from cells expressing eNOS alone or ER␣ plus myristoylation-deficient mutant eNOS were insensitive. In fact, membranes from cells expressing myristoylation-deficient mutant eNOS and ER␣ displayed a decline in NOS activity with E 2 that was partially reversed by ICI 182,780. A myristoylation-deficient mutant eNOS is minimally directed to the plasma membrane but unaltered in enzymatic activity (120), these findings indicate that both normal plasma membrane targeting of eNOS and localization of ER␣ to that site are required for eNOS activation by E 2 (123) .
C. Localization of ER␣-eNOS interaction to caveolae
Since plasma membrane eNOS is exclusively localized to caveolae (120) , further experiments were done to determine whether ER␣ protein is also associated with this subfraction of endothelial cell plasma membranes. ER␣ protein was detected in caveolae, and it was also detected, but to a lesser extent, in the noncaveolae fraction of the plasma membrane (Fig. 17A ). Experiments were then performed to evaluate the capacity of E 2 to activate eNOS in isolated caveolae and noncaveolae fractions. In the absence of added calcium, calmodulin, or cofactors, there was no measurable NOS activity in the noncaveolae fraction under basal conditions or with E 2 added. Basal NOS activity was also below detection limits in caveolae membranes. However, 10
Ϫ8 m E 2 caused robust activation of NOS in caveolae membranes, and this effect was prevented by ICI 182,780 (Fig. 17B) . These data strongly indicate that ER␣ and all of the additional molecular machinery necessary for E 2 -mediated activation of eNOS exist in a functional signaling module in endothelial caveolae. Since ER␣ was found in both caveolae and noncaveolae fractions and eNOS is solely in caveolae (120), the specificity of ER␣ coupling to eNOS to caveolae is evidently due to the localization of the effector, and not the receptor, in the microdomain. Furthermore, the effect of E 2 on eNOS in caveolae is prevented by calcium chelation (123) , suggesting that ER␣ activation in caveolae modifies the local calcium environment.
D. Role of ER␤ in nongenomic eNOS activation
ER␣ and ER␤ expression have both been observed in endothelial cells in multiple paradigms (14) . To determine whether endogenous ER␤ plays a role in nongenomic eNOS activation, studies have been performed recently in ovine endothelial cells that display constitutive expression of both isoforms. It was found that a subpopulation of endogenous ER␤ is localized to the endothelial cell plasma membrane, overexpression of ER␤ in endothelial cells enhanced rapid eNOS stimulation by E 2 , and the response to endogenous ER activation was inhibited by the ER␤-selective antagonist THC. In addition, eNOS activation through ER␤ was reconstituted and shown to occur independent of ER␣ in COS-7 cells (123a) .
Further experiments were done in isolated cell membranes to delineate the localization of ER␤-eNOS coupling. It was observed that THC blunts E 2 activation of eNOS in isolated endothelial cell plasma membranes. In addition, ER␤ protein was detected, THC attenuated E 2 stimulation of eNOS in isolated endothelial cell caveolae, and functional ER␤-eNOS coupling was recapitulated in caveolae from transfected cells (123a). Thus, both ER␣, as described above, and ER␤ have nongenomic action in endothelial cell caveolae to regulate eNOS activity in this specialized subcellular domain.
E. Coupling of plasma membrane ER to downstream signaling events
The basis by which signaling events are initiated by plasma membrane ER is perhaps best understood in the context of the known processes underlying eNOS activation by classical agonists such as Ach and bradykinin. These agents activate specific plasma membrane-associated G protein-coupled receptors (GPCRs) (124, 125) . G proteins are heterotrimers of ␣-, ␤-, and ␥-subunits (G ␣␤␥ ) that dissociate into G ␣ and G ␤␥ upon GPCR stimulation, after which activated G ␣ and/or G ␤␥ modulate the activity of downstream effector molecules. Based on sequence and functional similarities, the ␣-subunits are divided into four subfamilies: G ␣s , G ␣i , G ␣q , and G ␣12/13 (126, 127) . Within this context, the potential role of G proteins in the coupling of ER to downstream signaling events has been investigated in endothelial cells (128) . The first approach employed was to measure E 2 -stimulated eNOS activity in the absence or presence of pertussis toxin treatment, which inhibits G ␣ function by causing ADP ribosylation of a conserved cysteine at the fourth position (129). Intact endothelial cells were pretreated with vehicle or pertussis toxin and exposed to either the known GPCR agonist Ach (10 Ϫ5 m) or E 2 (10 Ϫ8 m) for 15 min. In the absence of pertussis toxin, Ach and E 2 caused comparable eNOS stimulation. As expected, eNOS activation by Ach was fully blocked by pertussis toxin. Similarly, eNOS stimulation by E 2 was prevented by pertussis toxin (Fig. 18A) . In contrast, pertussis toxin did not prevent eNOS activation by the calcium ionophore A23187. The inhibition of ER-mediated eNOS activation by pertussis toxin implicates G ␣i subfamily members only, of which G ␣i is expressed in endothelial cells and G ␣o is not (127, 129, 130) .
To further define the role of G proteins in E 2 -stimulated eNOS activation by an independent means, the effect of exogenous guanosine 5Ј-O-(2-thiodiphosphate) (GDP␤S) on eNOS stimulation by E 2 was evaluated in isolated endothelial cell plasma membranes. When membranes were exposed to E 2 alone, eNOS activation was apparent. However, when GDP␤S was added, eNOS stimulation by E 2 was inhibited by 70% (Fig. 18B ). E 2 -stimulated eNOS activity was not affected by GTP or GTP␥S (128) .
To confirm the observations made in endothelial cells and to provide a model system amenable to manipulation by cotransfection, the effect of pertussis toxin on E 2 -stimulated NOS activity was determined in COS-7 cells transfected with eNOS and ER␣ (Fig. 18C) . As observed in primary endothelial cells, E 2 treatment (10 Ϫ8 m for 15 min) caused eNOS stimulation that was completely blocked by pertussis toxin; in contrast, cells transfected with eNOS alone were not responsive to E 2 (107) . These cumulative data indicate that G ␣i mediates estrogen stimulation of eNOS. Pertussis toxin also prevented E 2 -mediated phosphorylation of MAPK in endothelial cells, indicating that G protein coupling occurs proximal to tyrosine kinase-MAPK activation in the series of events leading to eNOS stimulation (128) .
Potential interactions between plasma membrane ER␣ and G ␣ proteins have been evaluated in coimmunoprecipitation studies using COS-7 cells transfected with ER␣ and either G ␣i2 , G ␣q , or G ␣s (Fig. 19A) . Immunoprecipitation was performed with ER␣ antibody on plasma membranes from cells treated with vehicle or 10 Ϫ8 m E 2 for 20 min. In plasma membranes from quiescent cells, G ␣i , G ␣q , and G ␣s were minimally coimmunoprecipitated with ER␣. However, the association of G ␣i with ER␣ was markedly greater after E 2 stimulation. In contrast, the association of G ␣q and G ␣s with ER␣ remained negligible after E 2 treatment. Identical findings were obtained in endothelial cells (Fig. 19B) . Thus, in both an overexpression system and at constitutive levels of abundance, ER␣ activation by agonist leads to interaction between the receptor and G␣ i . All known GPCRs have seventransmembrane spanning domains linked by alternating intracellular and extracellular loops, and extensive experimentation indicates that the GPCR intracellular domains function in the direct signal propagation to G ␣␤␥ (126, 131) . Since the structure of ER␣ is entirely different from any known GPCR, it is unlikely that ER␣-G ␣i interaction is direct. Alternatively, ER␣ may be coupled to a classical GPCR that interacts directly with G ␣i . There is evidence that cross-talk of this type can occur to enable non-GPCR to perform G protein-mediated functions, such as the direct protein-protein coupling of ␥-aminobutyric acid A receptors to dopamine D5 receptors in hippocampal neurons. The cross-talk involves specific domains on both the non-GPCR undergoing ligand activation and the GPCR interacting with G protein (132). The third possibility is that ER␣-G␣i interaction requires an intermediary protein that is not a GPCR (128) .
Upon stimulation of classical GPCR, either the activated G ␣ -or G ␤␥ -subunits modulate the activity of downstream effectors (130). The potential roles of activated G ␣ or G ␤␥ in E 2 -induced activation of eNOS have been distinguished by assessing the impact of overexpression of G ␣i2 in COS-7 cells expressing ER␣ and eNOS (Fig. 20A) overexpression augmented E 2 -mediated eNOS stimulation by 3-fold, and pertussis toxin completely blocked the enhanced response. G ␣i1 overexpression had similar effects. The role of activated endogenous G ␣i was further substantiated in experiments assessing the effect of overexpression of a protein regulator of G protein signaling (RGS), RGS4 (Fig. 20B ). RGS4 attenuates signaling by accelerating the GTPase activity of members of the G ␣i and G ␣q subfamilies, but not that of G ␣s or G ␣12/13 (133). In COS-7 cells expressing ER␣ and eNOS that were cotransfected with RGS4 cDNA, E 2 -mediated eNOS stimulation was decreased by 90% compared with sham-transfected cells. These cumulative observations indicate that activated G␣ i mediates the downstream signaling processes that ultimately lead to eNOS activation. In addition to explaining the proximal events underlying nongenomic effects of estrogen in endothelial cells, these observations provide further support of a role for G proteins in nongenomic actions of estrogen in other cell types such as osteoblasts and macrophages (134, 135). There is also accumulating evidence that certain nongenomic actions of glucocorticoids, vitamin D 3 , and testosterone involve steroid hormone receptors acting through pertussis toxin-sensitive mechanisms (136 -139). It is proposed that the processes by which plasma membrane ER␣ are coupled to G ␣i in endothelial cells constitute not only the basis of nongenomic estrogen action in vascular and nonvascular cells, but also a means by which other steroid hormones may have important nonnuclear effects.
VI. Summary and Future Directions
The momentum of evidence in both human studies and animal models indicates that estrogen has potent stimulatory effects on eNOS expression and activity in vascular endothelium. The effects on eNOS abundance are perhaps more predictable and are primarily transcriptionally based, and they are ER dependent but ERE independent and most probably entail an Sp1 binding element within the core eNOS promoter. Estrogen also has potent nongenomic effects on eNOS activity mediated by a subpopulation of ER␣ localized to caveolae in endothelial cells, where they are coupled to eNOS in a functional signaling module (Fig. 21) . Emphasizing the dependence on cell surface-associated receptors, these observations provide evidence for the existence of a steroid receptor fast-action complex, or SRFC, in caveolae. Estrogen binding to ER␣ within caveolae leads to G␣ i activation, which mediates downstream events. The downstream signaling includes activation of tyrosine kinase-MAPK and Akt/protein kinase B signaling, stimulation of HSP90 binding to eNOS, and perturbation of the local calcium environment, ultimately leading to eNOS phosphorylation and calmodulin-mediated eNOS stimulation. The resulting combination of genomic and nongenomic mechanisms by which estrogen modulates eNOS plays a critical role in vascular health.
The current and future challenges in this area of research are numerous. The mechanisms by which estrogen upregulates eNOS expression warrant further study. In addition to eNOS, estrogen modifies the expression of other endothelial cell genes such as cyclooxygenase type 1 (140), and the processes underlying these effects are yet to be determined. Novel endothelial cell gene targets should also be sought. Our knowledge of the nongenomic basis of estrogen action in endothelial cells is also currently limited. Although immunocytochemical analyses suggest that the ligand binding domain of cell surface-associated ER␣ may be extracellular (119) , the orientation of plasma membrane ER␣ is yet to be elucidated. The mechanisms by which ER␣ is mem- brane associated and the processes regulating the relative number of cell surface ER␣ are not well understood. The basis for ER␣-G␣ i interaction, which may involve a classical GPCR or an alternative intermediate protein, is also entirely unknown. Furthermore, the proximal signal transduction events following G␣ i activation deserve in-depth study. Our present knowledge of eNOS modulation by estrogen typifies but a fraction of what may ultimately be a total of four categories of ER action. These categories are 1) membrane-initiated, nongenomic actions; 2) membrane-initiated, genomic actions; 3) non-membrane-initiated, nongenomic actions; and 4) non-membrane-initiated, genomic actions. When one considers that there are not only ER-dependent but also ER-independent mechanisms of estrogen response in certain paradigms, there are actually eight categories of possible estrogen action. These categories should be kept foremost in mind as we probe further into the bases for estrogen effects on the vasculature and other nonreproductive target organs.
Importantly, within the eNOS realm and elsewhere, the physiological and pathophysiological impact of the different modes of estrogen and ER action is yet to be delineated in intact model systems. It is only through such focused efforts that deeper understanding will be gained about processes including novel means of genomic estrogen action and ER function in a SRFC in caveolae. It is further anticipated that we will discover that other steroid hormone responses are either fully compartmentalized or at least initiated in SRFC on the plasma membranes of other cell types. Estrogen reduces atherosclerotic lesion development in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA 93:10022-10027 60. Holm P, Andersen HO, Nordestgaard BG, Hansen BF, Kjeldsen K, Stender S 1995 Effect of oestrogen replacement therapy on development of experimental arteriosclerosis: a study in trans-
